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Drugs with poor lipid and water solubility are some of the most challenging to formulate in nanocarriers, 
typically resulting in low encapsulation efficiencies and uncontrolled release profiles. PEGylated nano-
capsules (PEG-NC) are known for their amenability to diverse modifications that allow the formation of 
domains with different physicochemical properties, an interesting feature to address a drug encapsulation 
problem. We explored this problem by encapsulating in PEG-NC the promising anticancer drug candidate 
F10320GD1, used herein as a model for compounds with such characteristics. The nanocarriers were pre-
pared from Miglyol®, lecithin and PEG-sterate through a solvent displacement technique. The resulting 
system was a homogeneous suspension of particles with size around 200 nm. F10320GD1 encapsulation 
was found to be very poor (<15%) if PEG-NC were prepared using water as continuous phase; but we 
were able to improve this value to 85% by fixing the pH of the continuous phase to 9. Interestingly, this 
modification also improved the controlled release properties and the chemical stability of the formulation 
during storage. These differences in pharmaceutical properties together with physicochemical data sug-
gest that the pH of the continuous phase used for PEG-NC preparation can modify drug allocation, from 
the external shell towards the inner lipid core of the nanocapsules. Finally, we tested the bioactivity of the 
drug-loaded PEG-NC in several tumor cell lines, and also in endothelial cells. The results indicated that 
drug encapsulation led to an improvement on drug cytotoxicity in tumor cells, but not in non-tumor en-
dothelial cells. Altogether, the data confirms that PEG-NC show adequate delivery properties for 
F10320GD1, and underlines its possible utility as an anticancer therapy. 
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Effective drug encapsulation and controlled release are key properties of drug nanocarriers. It has been 
frequently stated that nanocarriers can impart beneficial biopharmaceutical properties to active molecules, 
including enhanced solubility, higher cellular and tissue penetration, reduced side effects, and improved 
biodistribution [1-5]. However, premature release of the drug from the nanocarrier, a most frequent situa-
tion, would ruin any of these benefits [6]. To be effective, nanocarriers need to be engineered to ensure 
tight integration between drugs and nanocarriers, and to attain drug release with appropriate kinetics. 
A particularly challenging type of drugs for formulation in nanocarriers are those with modest solubility 
both in oils and in water. Due to the limited affinity of the drug for the different domains of the nanoca-
rriers, these compounds will usually present poor encapsulation and uncontrolled burst release [7-8]. This 
has been observed for a variety of nanocarriers including liposomes, nanoemulsions, and polymeric na-
noparticles [9-12]. 
PEGylated nanocapsules (PEG-NC) are colloidal drug delivery systems characterized by an oily core and 
a highly structured PEG-lipid shell. We hypothesized that PEG-NC could be useful for formulating cha-
llenging drugs such as those described above due to the possibility to optimize drug-oil affinity by tech-
nological approaches [13]. Besides, PEG-NC are excellent nanocarriers for intravenous drug administra-
tion: they can be prepared using excipients with an acceptable regulatory status, and through industry-
friendly procedures. The nanocapsules’ PEG-coating endows the system with adequate stability in physio-
logical media, and eventually, with long-circulation properties upon intravenous administration that are 
beneficial for passive targeting to tumoral and inflamed regions [14-15].  
We have previously shown that the incorporation of PEG-stearate (PEG-STE, Symulsol® M52) to lipid 
formulations leads to the formation of dense polymeric coatings, above 2 chains/nm2, that are ideal for 
protein repulsion and stealth properties [16-18]. Moreover, PEG-STE may form phase-separated solid 
lipid layers on the surface of the nanocapsules, which could act as a diffusional barrier to prevent drug 
leakage. Indeed,we have previously measured the diffusion coefficients of PEG-STE coated nanoparticles 
by NMR and we have found that while the diffusion coefficient of the particles was 9,9x10-13m2s-1 (co-
rresponding to the Brownian motion of a sphere of 200nm, the size of the nanoparticle), the observed 
diffusion coefficient for the oil inside the particle was 35 times higher and similar to the pure oil 
(3x10-11m2s-1), indicating the confinement of the oil inside the protective PEG-STE monolayer [19]. We 
hypothesized that the presence of a solid surfactant shell on the surface could be useful to impart contro-
lled release to PEG-NC loaded with drugs with modest solubility in water and oils, providing we were 
able to integrate the drug in the lipid core of the nanocarrier. 
In this manuscript, we report the design of PEG-NC for the delivery of F10320GD1, an anticancer drug 
candidate used herein as a model compound exhibiting modest solubility in water and in oils. In order to 
improve the encapsulation of F10320GD1 into PEG-NC, we fixed the pH of the continuous aqueous pha-
se during nanocarrier preparation, a strategy previously used with other systems [9, 20-21]. Our results 
indicate that this modification leads to important changes in the characteristics of the formulation that 
cannot be attributed to a simple shift in partition equilibria, but rather to modifications in the structure of 
the nanocarrier-drug interaction. This formulation strategy could be potentially extended for encapsula-
ting other drugs with similar characteristics in structured lipid nanocarriers. !
2 MATERIALS AND METHODS 
2.1. Materials 
Soybean lecithin (EPIKURON® 170) was donated by Cargill (Spain). Miglyol® 812 (caprylic and ca-
pryc fatty acid esters) was donated by Sasol Germany GmbH (Germany). Polyethylene glycol stearate 
(PEG-STE, Symulsol® M52, MW=1750 Da) was donated by Seppic (France). Poloxamer 188 (Pluro-
nic® F68) was purchased by Sigma-Aldrich, Spain. The anticancer drug candidate F10320D1 was provi-
ded by FAES FARMA S.A. (Spain).  
!
2.2. Preparation of PEGylated nanocapsules 
PEGylated nanocapsules (PEG-NC) were prepared by a solvent displacement method [22]. For these sys-
tems, 25 mg of lecithin were dissolved in 10 mL of a acetone:ethanol (10:1 v:v) mixture in presence of 
variable amounts (0, 14, 34 or 68 µmol) of polyethylene glycol stearate (PEG-STE) and 0.125 ml of Mi-
glyol®. This organic phase was poured into 20 mL of an aqueous phase composed of poloxamer 188 
(0.25% w/v) under stirring, leading to the immediate formation of a milky dispersion. Finally, the organic 
solvents were removed under vacuum, and the PEG-NC were concentrated to a fixed volume of 10mL.  
Drug loaded PEG-NC were prepared by the method described above, but adding the drug to the organic 
phase together with the oil and the surfactants. PEG-NC prepared with controlled pH were prepared by 
the same method, but the continuous aqueous phase contained both poloxamer 188 and a sodium carbona-
te (Na2CO3) buffer adjusted to pH 9. 
!
2.3. Physico-chemical characterization of PEG-NC 
The particle size and polydispersity index of PEG-NC were measured by photon correlation spectroscopy 
(PCS). Samples were diluted in MilliQ water and the analysis was performed at fixed temperature with an 
angle detection of 90º. Z-potential was calculated from the mean electrophoretic mobility values determi-
ned by laser Doppler anemometry (LDA). Samples were diluted with potassium chloride (KCl) 1 mM 
and placed in an electrophoretic cell where a potential of ±150 mV was applied. PCS and LDA analysis 
were performed using a Zetasizer 3000HS (Malvern Instruments, Malvern, U.K.). Each sample was 
analyzed in triplicate. 
The morphological examination of the PEG-NC was performed by transmission electron microscopy 
(TEM, CM12 Philips, Netherland). Samples were stained with sodium phosphotungstic acid 2% (w/v), 
and placed on copper grids with Formvard® for visualization.    
The degree of PEGylation of the nanocapsules was assessed by 1H-NMR, after isolation by ultracentrifu-
gation of PEG-NC from non-associated PEG-STE (27400 g, 1 hour, 4 ºC) [16]. After isolation, the sam-
ples were diluted in deuterium oxide (D2O) and analyzed in a Bruker DRX 500 spectrophotometer. 
!
2.4. Encapsulation efficiency (E.E.) of loaded PEG-NC  
 The encapsulation efficiency of F10320GD1 in PEG-NC was determined by calculating the difference 
between the total amount of drug present in the formulation and the free drug found in the supernatant of 
the formulation after centrifugation. The total concentration of drug in the formulation was measured by 
dissolving an aliquot in acetonitrile and analyzing the drug content by high-performance liquid chromato-
graphy (HPLC). The free drug concentration was measured by the same method following separation 
from the encapsulated drug by ultracentrifugation (27400 g, 1 hour, 4 ºC). F10320GD1 quantification by 
HPLC was performed according to an analytical method provided by FAES FARMA S. A. 
!
2.5 Stability studies 
The stability of blank PEG-NC was evaluated under storage for 90 days at 4ºC, 25ºC and 37ºC. Particle 
size, polydispersity index (P.I.) and Z-potential was assessed at different time points and measured as 
described above. Drug concentration and encapsulation efficiency of drug loaded PEG-NC was also eva-
luated under storage conditions for 30 days at 4ºC using the methods described above. 
The stability of blank PEG-NC was also evaluated after 24 hours incubation at 37ºC in different aqueous 
solutions: saline solution 0.9% (w/v), supplemented medium DMEM+, PBS and water. Size and polydis-
persity index were measured after 24 hours as described above. 
!
2.6 In vitro release studies 
Release studies were carried out by incubating loaded PEG-NC in PBS at an appropriate concentration to 
ensure sink conditions. The samples were placed in an incubator at 37ºC with horizontal shaking and co-
llected at different time intervals. The percentage of drug released was quantified by HPLC after separa-
tion of the encapsulated drug by ultracentrifugation as described in 2.4.  
!
2.7 Cell culture 
The cytotoxic effect of the free and encapsulated drug was evaluated in four different human cell cultures. 
Three human cell lines were used, MCF7, SF268, and NCI-H460, models for breast, glioblastoma and 
lung cancer, respectively. The cytotoxicity was also tested in a primary culture of human umbilical vein 
endothelial cells (HUVEC). The human cell lines used in this study were obtained from the American 
Type Culture Collection (ATCC), and they were cultured in RPMI-1640 medium containing 10% (v/v) 
heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin 
at 37ºC in humidified 95% air and 5% CO2. HUVEC were obtained by collagenase digestion of umbilical 
cord veins as described elsewhere [23], and cultured under the same conditions.  !
2.8 Cell viability assay 
Cell viability was determined by an XTT colorimetric method. Known amounts of exponentially growing 
cells were seeded in 96-well flat-bottomed microtiter plates, at a final volume of 100 µl. Seeded cells 
were incubated for 24 h at 37°C, in a humidified atmosphere of 5% CO2/95% air to allow cell attachment 
to the plates. Then, cells were incubated for 72 h with different concentrations of the tested formulations 
or controls, under standard culture conditions. Cell proliferation was quantified using the XTT (3'-[1-
(phenylamino)carbonyl]-3,4-tetrazolium-bis(4-methoxy-6-nitro)benzene sulfonic acid sodium salt hy-
drate) cell proliferation kit (Roche Molecular Biochemicals, Mannheim, Germany) following the manu-
facturer’s instructions. Briefly, a freshly prepared mixture solution (50 µl) of XTT labeling reagent and 
PMS (N-methyldibenzopyrazine methyl sulfate) electron coupling reagent was added to each well. The 
resulting mixtures were incubated for 4 h in a humidified atmosphere (37°C, 5% CO2), and the ab-
sorbance of the formazan product generated was measured in a microtiter plate reader at a test wavelength 
of 490 nm and a reference wavelength of 655 nm. The IC50 (50% inhibitory concentration) was calculated 
as the drug concentration causing a 50% inhibition in cell proliferation. Data is represented as mean val-
ues of four independent experiments each performed in triplicates. The drug concentrations tested were 
20, 10, 5, 1, 0.1µM. !
2.9 Statistical analysis 
All statistical analyses were performed using the software OriginPro (Northampton, MA, US). Experi-
ments were analyzed using a one-way analysis of variance (ANOVA) followed by Tukey's test to deter-
mine the significance of all paired combinations. Differences were considered to be significant at a level 
of p < 0.05. !!
3 RESULTS & DISCUSSION 
In this work, we have developed a nanotechnology formulation strategy that enables the encapsulation of 
drugs with poor solubility both in water and in oils, and its controlled release from the nanocarriers. The 
nanocarriers, PEGylated nanocapsules (PEG-NC), consist on an oily core stabilized with a PEG-stearate 
(PEG-STE) shell. To address this formulation challenge, a promising anticancer drug candidate, 
F10320GD1, was used as a model for compounds with these physicochemical properties. The developed 
PEG-NC loaded with F10320GD1 were characterized with respect to their size, zeta potential, stability, 
encapsulation efficiency and controlled release properties. Finally selected prototypes were selected for 
the evaluation of their activity in cell cultures. !!
3.1 Preparation and characterization of PEG-NC 
We designed PEG-NC based on a triglyceride oil (Miglyol® 812), and a tensoactive (lecithin), materials 
with known utility for the encapsulation of hydrophobic and amphipilic drugs, and suitable for i.v. injec-
tion [24-25]. We also incorporated a protective PEG coating around the nanostructure by including PEG-
STE as an additional component. The use of PEG-linked lipids has been previously described as an effec-
tive strategy to PEGylate lipid systems that avoids chemical conjugation and the use of costly PEGylated 
phospholipids [26-28]. PEG-NC were prepared following a solvent displacement technique, a simple and 
mild method that is easily scalable. PEG-NC formation was assessed by transmission electron micros-
copy (TEM) and photon correlation spectroscopy (PCS) measurements. 
In a first step, we aimed at studying the amount of PEG-STE necessary to achieve a suitable surfactant 
shell. Previous studies from our group have shown that lipid nanocarriers can be coated with PEG by the 
addition of PEG-STE, achieving polymer densities that should be suitable for stealth nanocarriers [16]. In 
this work, we studied different proportions of PEG-STE in the lipid mixture (0-60% w/w), and analyzed 
its effect on nanocarrier structure and morphology, particle size, and Z-potential. 
 TEM images indicated that PEG-NC are homogeneous, with spherical morphology, and particle size 
around 200 nm (Figure 1). The presence of different amounts of PEG-STE affected neither the size nor 
the morphology of PEG-NC, but at 60% (w/w) PEG-STE  another population of small particles appeared 
in the TEM images. This second population can be attributed to the formation of PEG-STE micelles once 
the PEG-NC shell is saturated. 
The results obtained by TEM were confirmed by dynamic light scattering (Table 1). All PEG-NC showed 
a low polydispersity index (P.I.) (below 0.2 in all cases) and a mean size between 150-200 nm. The inclu-
sion of the non-ionic polymer PEG-STE in the formulation did not significantly affect the hydrodynamic 
diameter of PEG-NC, however, a neutralization of the Z-potential value (from -38 to -22 mV) was noted 
as the amount of PEG-STE was increased to 30-60% (w/w). The variation of the Z-potential with the con-
tent of PEG-STE can be attributed to a shielding effect of PEG on the nanocapsule surface, and is a typi-
cal observation for PEGylated colloidal systems. Based on the fact that further reductions in Z-potential 
were not observed between 30 and 60% (w/w), and on the observation of a second population of micellar 
structures for the highest PEG-STE proportion (see above), we decided to fix this parameter for future 
studies at 30% (w/w). 
NMR studies performed on isolated PEG-NC confirmed the PEGylation on the nanocapsules. PEG-NC 
were washed by centrifugation to remove the non-bound PEG-STE and then analyzed by 1H-NMR. A 
well resolved peak was observed at 3.6 ppm, thus confirming the presence of PEG on the formulation 
[16] (Supplementary material, Figure S1). 
The stability of PEG-NC was tested in different media upon incubation at 37ºC for 24 hours (Figure 2). 
PEG-NC showed good stability both in water and in supplemented medium (D-MEM). However, in solu-
tions with higher ionic strength such as saline solution or PBS, particle aggregation was observed. To 
increase the stability of PEG-NC in these media, poloxamer 188 was included in the formulation. The 
results showed that the addition of poloxamer 188 did not alter the size or the Z-potential of the resulting 
PEG-NC, however their stability in PBS and saline solution was significantly increased. Indeed, no ag-
gregation was observed after 24 hours at 37ºC in these media. Steric stabilization of nanocapsules by non-
ionic surfactants, has been previously described, and it is considered essential to preserve the colloidal 
characteristics in physiologically fluids [29]. In this work, PEG-STE and poloxamer 188 seem to work 
cooperatively to achieve an optimal colloidal stability in buffered media with ionic strength and pH simi-
lar to those of plasma. 
Finally, we tested the stability of PEG-NC upon storage for three months at different temperatures (4, 25 
and 37ºC). This stability was assessed by measuring the size and P.I. of PEG-NC at different times during 
this incubation period. Neither particle aggregation nor size increase due to Ostwald ripening was obser-
ved for up to 90 days, not even at 37ºC (Figure 3). 
Based on all this characterization, the final composition of PEG-NC used throughout this work was selec-
ted: Miglyol® 55% w/w, lecithin 12% w/w, PEG-STE 28% w/w and poloxamer 5% w/w. 
!!
3.2 Encapsulation of F10320D1 in PEG-NC 
Hydrophilic macromolecules can be encapsulated in liposomes and in some polymeric nanoparticles with 
relatively high efficacy [30-32], whereas highly hydrophobic drugs are good candidates to be entrapped 
in lipid-based formulations (liposomes, nanocapsules, lipid nanoparticles, nanoemulsions) [33-34]. Ho-
wever, drugs with limited solubility both in lipid an aqueous media, often prove difficult to encapsulate in 
nanocarriers.  
We have previously described several modifications that can be applied to the core and the shell of lipid 
nanocarriers [16, 19, 26]. Based on this structural flexibility of lipid nanocarriers, we proposed the poten-
tial interest of PEG-NC as delivery systems for drugs with poor solubility both in water and in oils. Besi-
des these considerations, PEG-NC offer other additional advantages considering future applications for 
the model cytotoxic drug used in this study: F10320D1. Namely, their dense PEG shell will allow these 
nanocarriers to circulate for a prolonged time in the  bloodstream and accumulate in solid tumors by pas-
sive targeting [35-36]. 
F10320D1 has the following physicochemical characteristics: low molecular weight (~ 450 Da), pKa 
between 8-9, low solubility in water (0.5 mg/mL, 1mM) and also in oils. PEG-NC formation proceeded 
normally in the presence of the drug, resulting in the instantaneous formation of a homogeneous colloidal 
systems. Unfortunately, when we prepared PEG-NC with loadings suitable to reach final drug concentra-
tions optimal for in vivo experiments (2 mg/mL, 4mM), the encapsulation efficiency (E.E.) was unaccep-
table (15%). The low EE value obtained was attributed to the low solubility of the drug in the oily phase 
that forces drug allocation towards the negatively charged PEG-NC surface.  
In order to increase the E.E. and the loading capacity of PEG-NC, we applied a simple modification of 
the solvent displacement technique that consists on buffering the continuous aqueous phase used for na-
nocarrier preparation at pH 9 with sodium carbonate (buffer concentration 10 mM) [9, 21]. The resulting 
E.E. value was 85% for a drug concentration of 2 mg/mL. This change implied a 7-fold increase, both in 
E.E. and real drug loading as compared to the non-modified solvent displacement technique. Interestin-
gly, similarly high E.E. (≈90%) could be achieved with the standard PEG-NC if working at lower drug 
concentration (50 µg/mL).  
Table 2 shows the physicochemical characterization of blank and drug-loaded PEG-NC prepared at diffe-
rent pH values: 7 and 9. It can be seen that, at any pH, the size of both PEG-NC increases after drug en-
capsulation, from 175 nm to 250 nm; this is probably due to the incorporation of significant amounts of 
drug to the nanocarriers. Analysis of PEG-NC surface charge by Z-potential shows significant differences 
between the two formulations. Blank PEG-NC showed negative Z-potential values at both pH values 
(both around -20 mV), caused mainly by the presence of phospholipids on their surface, which remain 
negatively charged at any pH. However, the Z-potential of PEG-NC prepared at pH 7 is dramatically in-
verted upon drug encapsulation, going from -20 mV to +38 mV. This inversion of the Z-potential could 
only be attributed to the presence of positively charged drug on the PEG-NC surface. Interestingly, this 
inversion in the Z-potential value was not observed for PEG-NC prepared at pH 9, even at this high drug 
concentrations.  
This difference in behavior regarding E.E. and Z-potential of PEG-NC prepared at pH 7 and pH 9 can be 
explained by two non-excluding hypothesis. First, by deprotonation of the drug on the PEG-NC surface at 
pH 9. Another explanation would be that deprotonated F10320D1 becomes more affine for the oil, and 
that this change results in its preferential allocation in the nanocarrier core (Scheme 1). Further studies 
suggest that this last hypothesis should account for most of the observed effect (see 3.3 and 3.4).  !!
3.3 Stability studies with drug-loaded formulations. 
Drug-loaded PEG-NC were stored at 4 ºC for 1 month and size, P.I., drug concentration and E.E. were 
measured at different time points to evaluate the stability of the selected formulations. Size and P.I. re-
mained unchanged for PEG-NC prepared at pH 7 and pH 9: size≈250 nm and P.I.≈0.15 (Supplementary 
Figure S2). These results indicate adequate colloidal stability of the nanocarriers when stored at 4ºC for 
prolonged periods. The stability of the drug-loaded PEG-NC in terms of size and zeta potential was simi-
lar to that of blank PEG-NC, which indicates that the presence of drug does not affect the physicochemi-
cal stability of the PEG-NC.  
A different situation was observed when we analyzed the formulations drug content over time (Figure 4). 
PEG-NC prepared at pH 7 presented a dramatic diminution (80%) of encapsulated drug already after 15 
days of storage. In contrast, PEG-NC prepared at pH 9 showed no drug leakage after 1 month. Total drug 
concentration (encapsulated plus non-encapsulated) was also found to remain constant during the stability 
studies for PEG-NC prepared at pH 9, but not for those prepared at pH 7 (Supplementary information, 
Figure S3). The improved stability of PEG-NC formulated at pH 9 in comparison with those formulated 
at pH 7, could be explained by the efficient drug encapsulation within the inert oily core instead of being 
simply associated on the nanocarrier surface. !!
3.4 in vitro drug release 
In vitro drug release studies were performed under sink conditions in PBS at 37ºC (Figure 5). PEG-NC 
loaded with F10320GD1 and prepared at pH 7 and 9 were studied for release for a period of 8 hours. 
PEG-NC prepared at pH 7 presented an important burst release of around 50% of the drug payload, fo-
llowed by a plateau phase for the next 8 hours. This drug release profile is typical for most oily-based 
formulations such as polymer-coated nanocapsules [33, 37-39]. For PEG-NC formulated at pH 9, the 
burst effect was significantly reduced from 50% to 15%, and the amount of drug released after 8 h was 
still only 30% of the payload. Therefore, PEG-NC prepared at pH 9 showed a controlled release profile, 
in contrast with the uncontrolled behavior of PEG-NC prepared at pH 7. Sustained release profiles have 
been also observed from some lipid nanocarriers upon deprotonation of doxorubicin [40] and etoposide 
[27]. 
This difference in drug release profile is particularly remarkable because once in PBS all formulations are 
at the same pH, and therefore, partition and solubility equilibria should be equal for both PEG-NC inde-
pendently of their pH preparation value. Thus, the more sustained drug release profile observed for PEG-
NC prepared at pH 9 should be related to the drug allocation within the oily core, and the necessity to 
overcome a diffusional barrier to participate in solubility/partition equilibria. The diffusional barrier could 
be the phospholipid/PEG-STE shell as previous studies have shown that PEG-STE is preferentially dispo-
sed on the surface of lipid nanocarriers [16], and that this material can form packed lipid layers with a 
melting point between 40 and 51ºC depending on its physical form [19]. On this basis, a lecithin/PEG-
STE lipid layer could be an effective barrier to control drug release, providing that the drug is integrated 
in the nanocarrier's core. !!
3.5 In vitro antitumor efficacy studies. 
Finally, the bioactivity of F10320GD1 loaded into PEG-NC was assessed in different cell models. Cyto-
toxicity of F10320GD1 dissolved in 2% DMSO, drug loaded PEG-NC (300 µg/mL) and blank PEG-NC 
was evaluated in three different human tumor cell lines: MCF-7, NCI-H460 and SF-268 (from lung, 
breast and glioma, respectively). The formulations were also tested in human umbilical vein endothelial 
cells (HUVEC) to asses for differential toxicity in non-tumor cells. 
In all the tumor cell lines, there was a significant increase of the cytotoxic effect when the drug was en-
capsulated on PEG-NC as compared to the drug in solution (Figure 6). For instance, the IC50 in MCF-7 
cell line for non-encapsulated drug was 6.5 µM, while for the drug loaded in PEG-NC was 2.8 µM, a 
two-fold increase in efficacy. Similar results were obtained in NCI-H460, where PEG-NC delivery redu-
ced IC50 values from 16 µM to 9.5 µM. In SF-268, IC50 was reduced from 7.8 µM to 2.8 µM. The IC50 
values obtained for blank PEG-NC were 20-30 µM, depending on the cell line. This IC50 values are ex-
pressed as the corresponding drug concentration if blank PEG-NC would have been loaded with 
F10320GD1; these values are over 2-3 times higher than the drug alone, and they indicates that the for-
mulation should not be a relevant contributor to the toxic effect observed in drug-loaded samples per se.  
The increase in drug cytotoxicity when encapsulated in PEG-NC has previously been observed by other 
authors. For instance, the group of Benoit et al. observed a significant enhancement of the therapeutic 
effect of several drugs formulated in PEG-NC such as etoposide [27], tamoxifen [28], or paclitaxel [29]. 
In addition, Mumper et al. have also reported a decrease on the IC50 values of paclitaxel and doxorubicin 
after encapsulation in PEG-NC [11]. Having discarded a direct toxic effect of PEG-NC, the higher effi-
cacy of the drugs upon encapsulation in PEG-NC can be attributed to two effects: (a) the easier internali-
zation of the loaded PEG-NC into the cytosol as compared to the drug alone [27-28], or/and (b) the possi-
ble inhibition of the efflux mechanisms of the cancer cells due to the presence of PEG polymers or by the 
nanocapsules themselves [41-42]. In fact, it has been widely reported that poloxamer inhibits many cell’s 
efflux pumps, such as P-gP or MDR proteins, through different pathways [43].  
Cytotoxicity of F10320GD1 alone or formulated in PEG-NC as well as the PEG-NC alone was also tes-
ted in HUVEC, to check for tumor/non-tumor differential toxicity. The results showed a significant de-
crease of the IC50 values for loaded PEG-NC, but this decrease is unnoticeable as compared to that ob-
served in tumor cell lines. In addition, no cytotoxic effect was observed for blank PEG-NC in HUVEC 
cells, which confirms the low toxicity profile of this carrier over the studied concentrations. !!
4- CONCLUSIONS 
Herein we report on the nanoencapsulation of a challenging compound, with limited solubility in water 
and in oils, in PEGylated nanocapsules. High drug encapsulation efficacy with high drug payloads were 
achieved by controlling the pH of the continuous phase during the nanoencapsulation process. Besides, 
this control in the pH also resulted in other beneficial characteristics such as prolonged drug stability 
upon storage, and controlled release properties. The data obtained suggest that these improved properties 
might be linked to a change in drug allocation to the inner core of the nanocapsules caused by pH-depen-
dent deprotonation. In vitro testing in a cell culture panel indicated that the drug formulated in PEG-NC is 
bioactive, and even more efficacious than the drug itself, indicating improved intracellular delivery of the 
nanoencapsulated drug. We believe that the technological approach outlined in this work could be valua-
ble for formulating other similar compounds in structured lipid  nanocarriers. !
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TABLES !
Table 1. Effect of PEGylation on size, polydispersity index (P.I.), and Zeta potential of PEG-NC. Data are means 
±S.D., n=4. 
!!!
Table 2. Mean particle size distribution, polydispersity index (P.I. ), Zeta potential and Encapsulation efficiency 
(E.E.) of PEG-NC prepared with two different continuous phases: buffer pH 7 and buffer pH 9. Data are means 
±S.D., n=4. 
!!
% PEG-STE w/w Size (nm) P.I. Z-potential (mV)
0 184 ± 2 0.13 -38 ± 2
15 175 ± 7 0.12 -34 ± 2
30 176 ± 13 0.13 -22 ± 2
60 178 ± 21 0.12 -28 ± 2







PEG-NC (blank) 7 176 ± 5 0.13 -22 0 /
PEG-NC (blank) 9 176 ± 5 0.15 -16 0 /
PEG-NC (loaded) 7 239 ± 4 0.22 +38 2 15 ± 5 
PEG-NC (loaded) 9 241 ± 3 0.23 -12 2 85 ± 10 
FIGURES 
Scheme 1 Schematic illustration of the solvent displacement techniques described in this work for the formation of 
PEG-NC. 
#  !!
Table 1. Effect of PEGylation over size, P.I. and Zeta potential of PEG-NC. Data are means ±S.D., n=4 
!!
Table 2. Size, P.I. Zeta potential and Encapsulation efficiency (E.E.) of blank and loaded PEG-NC prepared in two 
different buffers at pH 7 and 9. Data are means ±S.D., n=4 
% PEG-STE w/w Size (nm) P.I. Z-potential (mV)
0 184 ± 2 0.13 -38 ± 2
15 175 ± 7 0.12 -34 ± 2
30 176 ± 13 0.13 -22 ± 2
60 178 ± 21 0.12 -28 ± 2







blank-PEG-NC 7 176 ± 5 0.13 -22 0 /
blank-PEG-NC 9 176 ± 5 0.15 -16 0 /
Loaded-PEG-NC 7 239 ± 4 0.22 +38 2 15 ± 5 
Loaded-PEG-NC 9 241 ± 3 0.23 -12 2 85 ± 10 
!
!
Figure 1. TEM images of blank PEG-NC prepared with different amounts of PEG-STE (% w/w): 0 (a), 30 (b) and 60 
(c). Scale bar= 200 nm. 
#  
!!
Figure 2. Size of PEG-NC in presence or in the absence of poloxamer, after 24 hours incubation at 37ºC in different 
media: water (control), saline solution 0.9%, supplemented medium (D-MEM+) and phosphate buffer (PBS). Data 





























Figure 3. Size of blank PEG-NCs upon storage at 4 ºC, 25 ºC and 37 ºC. Polydispersity index remained below 0.15 
in all cases. means ±S.D., n=4. 
 #  !
Figure 4. Variation of E.E. of loaded PEG-NC prepared at pH 7 and pH 9 under storage at 4ºC.  Initial drug concen-




































0 7 14 30
pH 7 pH 9
!
Figure 5. In vitro drug release profiles of PEG-NC prepared at pH 7 (black circles) and pH 9 (white squares) and 
incubated in PBS (pH=7.4) at 37ºC. Stars indicate the significant difference of data points compared with the pre-
vious one (* p<0.05). Data represents means ±S.D., n=4.  
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Figure 6.  Inhibitory concentration 50% (IC50) values obtained for the free drug (F10320GD1), loaded PEG-NC 
(loaded) and blank PEG-NC (blank) in: MCF-7, NCI-H460 and SF-268 tumor cell lines, and in Human Umbilical 
Vein Endothelial Cells (HUVEC) primary cultures. Data represents means ±S.D. n=12, four independent experiments 
each performed in triplicates. (* p<0.05, ** p<0.01, *** p<0.005).  
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